digi.bio

Executive Summary

Digi.Bio is a Dutch biotechnology company pioneering a single-cell, AI-driven, lab-on-a-chip platform that measures individual cell fate and performance—including cytotoxicity, motility, and interactions—to accelerate the development of next-generation therapies. The platform is cell- and therapy-agnostic, making it applicable to engineered T cells, antibodies, small molecules, and other modalities. Founded in 2019 and based in Amsterdam, the company addresses a critical bottleneck in drug development: the ability to rapidly and accurately assess which therapeutic candidates are most effective at the single-cell level. By combining microfluidics with machine learning, Digi.Bio offers a high-throughput, real-time window into cellular responses, potentially reducing the time and cost of bringing new therapies to market. The technology's broad applicability positions Digi.Bio as a key enabler in multiple therapeutic areas, from oncology to autoimmune diseases. As the biopharma industry increasingly adopts precision medicine, the demand for advanced phenotypic screening tools is growing. Digi.Bio's platform could become a standard for preclinical evaluation, particularly for cell and gene therapies where single-cell resolution is crucial. While the company remains private and has not disclosed funding details, its innovative approach and alignment with industry trends suggest significant potential. Key risks include competition from established players and the need to validate the platform across diverse therapeutic contexts. Overall, Digi.Bio represents a compelling opportunity in the digital health and AI-driven drug discovery space.

Upcoming Catalysts (preview)

• TBDStrategic partnership with a major pharma company60% success
• TBDSeries A or Series B funding round announcement70% success
• TBDPublication of validation data in a peer-reviewed journal50% success